Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation

Abstract

Sorafenib is an oral multikinase inhibitor used as a palliative intent for advanced hepatocellular carcinoma (HCC). Dermatologic toxicity is the main adverse effect limiting its use in many patients. However, Grade III dermatologic toxicity is rarely seen with low-dose sorafenib administration. Here, we discuss the case of a 72-year-old male patient who was treated with sorafenib 400 mg for HCC. After 18 days of administration, the patient complained of intense pain with blisters and ulcerations. The drug was discontinued, and topical corticosteroids and analgesics were given for the management. Review of the patient's medication did not reveal the presence of any other possible drugs capable of producing dermatological toxicity.